Global Diabetes Devices & Drugs Market (2011- 2016)
MARKET OVERVIEW
The Global Market for Diabetes Management accounted for USD 40 billion in 2010 and is expected to attain a market size of around USD 114 billion following a growth rate of 13.5% CAGR. The major products in this market consists of glucose meters, test strips, lancets, continuous blood glucose meters, syringes, insulin pumps, insulin and other insulin delivery devices and anti-diabetic drugs. However, insulin, test strips and anti-diabetic drugs are the most revenue generating products.
Among the different geographies across the globe, U.S. forms the main source of revenue for this market contributing for around 35% of the revenue. However, with the continuous economic growth of Asia-Pacific region especially that of China, the contribution of U.S. market is expected to drop by 5% to 7% with a period of 10 years from now.
Currently more than 275 million people are suffering from diabetes across the globe and this population is expected to exceed 425 million by 2030. As per the present scenario, the population within the age bracket of 40-59 years is the most affected. However, this age bracket is expected to shift to the age-group 60-79 years by 2030.
Out of the two major segments of Diabetes market globally, the Diabetes drug market accounts for approximately USD 28 billion with oral drug constituting around 38% and injectables contributing more than 55%. The other major segment of the global diabetes market, the device market, accounted for USD 16 billion in year 2010.
With the increase in population and change in lifestyle which is leading to obesity, the diabetic population is increasing rapidly. Also the lack in awareness about the Diabetes diagnostics and treatment, the countries with high population are leading to the expansion in the diabetic population worldwide.
With the participation of Pharma giants, this market is characterized as highly competitive market. The major players in Diabetes drugs market worldwide includes Abbott Laboratories, Novo Nordisk, Merck, Sanofi-Aventis etc. and those in device market include Johnson & Johnson, Roche, Bayer, Zydus Cadila etc.
Chapter 1 – Market Overview
1.1 Introduction
Chapter 2 – Market Metrics
2.1 Prevalence of Diabetes
2.2 Age-Group Analysis
Chapter 3 – Market Analysis
3.1 U.S. Diabetes Market
3.1.1 Drivers
3.1.1.1 Increase in awareness among diabetic population
3.1.1.2 Obesity as a leading cause of diabetes
3.1.2 Restraints
3.1.2.1 Undiagnosed Diabetic population
3.1.3 Opportunities
3.1.3.1 Increasing awareness may unleash the untapped market potential
3.1.4 Key Market Trends
3.2 EUROPEAN MARKET
3.2.1 Innovation driving the European market
3.2.1.1 Restraints
3.2.1.1.1 Case1
3.2.1.1.2 Case 2
3.2.1.1.3 Case 3
3.2.1.2 Undiagnosed patients high in European countries
3.2.1.3 Increasing R&D costs
3.2.2 Opportunities
3.2.2.1 Undiagnosed Diabetic Patient Population in Europe
3.2.3 Market Size & Growth rate
3.3 Asia-Pacific Diabetes Market
3.3.1 Market Overview
3.3.2 China
3.3.3 India
3.3.4 South Korea
3.3.5 Taiwan
3.3.6 Market Size & Growth rate
Chapter 4 – Global Diabetes Device Market
4.1 Insulin Pumps
4.1.1 Drivers
4.1.1.1 Growing Diabetic Population
4.1.1.2 Advancement in Technology
4.2 Global Self Monitoring Blood Glucose Market
4.2.1 Market Size & Growth Rate
4.2.1.1 Drivers
4.2.1.1.1 Increasing awareness and simpler devices
4.2.1.1.2 Increase in disposable income
4.2.1.1.3 Declining prices
4.2.1.1.4 Improving compatibility
4.2.1.2 Restraints
4.2.1.2.1 Increase in competition leading to low prices
4.2.1.2.2 Private Label Brands
4.2.1.2.3 Awareness among patients is still a challenge
4.2.2 Key trends
Chapter 5 – Competition Analysis
5.1 Continuous Glucose Monitor Market
5.1.1 Drivers
5.1.2 Restraints
5.1.3 Opportunity
5.2 Clinical Trials
Chapter 6 – Global Diabetes Drugs Market
6.1 Market Overview
6.1.1 Market Size and Growth Rates
6.2 Global Diabetes Injectables Market
6.2.1 Market Size & Growth rate
6.2.2 Drivers
6.2.2.1 Improved Delivery Devices
6.2.2.2 Increased risk with the Oral Anti-Diabetes Drugs
6.2.2.3 Technological Advancement
6.2.3 Restraints
6.2.3.1 Associated Pain
6.2.3.2 Market boom for New Generation diabetic drugs
6.2.3.3 Cost Issues
6.2.4 Opportunities
6.2.4.1 Novel insulin delivery method
6.3 Global Insulin Market
6.3.1 Global Non-Insulin Injectables Market
6.3.1.1 Drivers
6.3.1.2 Opportunities
6.4 Global Oral diabetes Drug Market
6.4.1 Market Size & Growth rate
6.4.2 Popular Anti-Diabetic Drugs World wide
6.4.3 Drivers
6.4.3.1 Novel drugs driving the market growth
6.4.3.2 Patent expiry of popular drugs
6.4.3.3 Painless Option
6.4.4 Restraints
6.4.4.1 Associated High Risks
6.4.4.2 Improving options of insulin delivery devices
6.4.4.3 Trend of diabetic diet
6.4.5 Opportunities
6.4.5.1 Diabetes Vaccines
6.4.5.2 Leveraging the patent expiry of popular drugs
Chapter 8 – Company Profiles
8.1 Abbott Laboratories
8.2 Bristol-Myers Squibb (BMS)
8.2.1 Recent Deals
8.3 Dexcom
8.3.1 Recent Deals
8.4 Eli Lilly
8.4.1 Recent Deals
8.5 GlaxoSmithKline
8.5.1 Recent Deals
8.6 Glenmark Pharmaceuticals
8.6.1 Recent Deals
8.7 Johnson&Johnson
8.7.1 Few Recent Deals
8.8 Lupin
8.8.1 Recent Deals
8.9 Roche
8.9.1 Recent deals
8.10 Sanofi
8.10.1 Recent Deals
List of Table:TABLE 1 Global Market Size & Growth Rate, By Geography (USD billion)
TABLE 2 Prevalance of Obesity among U.S. States
TABLE 3 Global Diabetes Device Market, By Product (in USD billion)
TABLE 4 Clinical Trials: United States (Insulin Pumps)
TABLE 5 CLINICAL TRIALS: UNITED KINGDOM (INSULIN PUMPS)
TABLE 6 Clinical Trials: France (Insulin Pumps)
TABLE 7 Clinical Trials: Germany (Insulin Pumps)
TABLE 8 Clinical Trials: China (Insulin Pumps)
TABLE 9 Clinical Trials: United States (Glucose Monitors)
TABLE 10 Clinical Trials: United Kingdom (Glucose Monitors)
TABLE 11 Clinical Trials: France (Glucose Monitors)
TABLE 12 Clinical Trials: China (Glucose Monitors)
TABLE 13 Global Anti-Diabetic Drug Market, By Product (in USD billion)
TABLE 14 Global Anti-Diabetes Injectables Drug Market, By Product (in USD billion)
TABLE 15 Clinical Trials: US (Oral Anti-Diabetes Drugs)
TABLE 16 Clinical Trials: China (Oral Anti-Diabetes Drugs)
TABLE 17 Clinical Trials: Japan (Oral Anti-Diabetes Drugs)
TABLE 18 Clinical Trials: India (Oral Anti-Diabetes Drugs)
TABLE 19 Clinical Trials: United Kingdom (Oral Anti-Diabetic Drugs)
TABLE 20 Clinical Trials: Germany (Oral Anti-Diabetic Drugs)
TABLE 21 Clinical Trials: France (Oral Anti-Diabetic Drugs)
TABLE 22 Clinical Trials: US (Anti-Diabetic Injectables)
TABLE 23 Clinical Trials: Japan (Anti-Diabetic Injectables)
TABLE 24 Clinical Trials: China (Anti-Diabetic Injectables)
TABLE 25 Clinical Trials: India (Anti-Diabetic Injectables)
TABLE 26 Clinical Trials: Germany (Anti-Diabetic Injectables)
TABLE 27 Clinical Trials: United Kingdom (Anti-Diabetic Injectables)
TABLE 28 Clinical Trials: Germany (Anti-Diabetic Injectables)
List of Charts:FIG. 1 Diabetic Population (Million)
FIG. 2 market share
FIG. 3 Shift in Diabetes Demography
FIG. 4 Prevalence of diabetes among various age groups
FIG. 5 GLOBAL OBESITY SCENARIO
FIG. 6 U.S. Diabetes Market Size
FIG. 7 Increasing Prevelance of Diabetes in U.S.
FIG. 8 Diagnosed Vs. Undiagnosed
FIG. 9 Diagnosed Vs. Undiagnosed Scenario by 2020E
FIG. 10 Drugs Vs. Devices Market Share
FIG. 11 Diabetes Prevalence in Europe
FIG. 12 Population Distribution with Diabetes (initiating DPP-IV, TZD, GLP-1 or Insulin)
FIG. 13 Undiagnosed Diabetic Population
FIG. 14 European Diabetes Drugs Market Share (By Volume)
FIG. 15 European Diabetes Market Size
FIG. 16 Distribution of Diabetes Drug Market in Europe
FIG. 17 Diabetes Prevalence in Asian Countries
FIG. 18 Asian Diabetes Market Size
FIG. 19 Key Participants: Market Shares (2010)
FIG. 20 Global Insulin Pumps Market
FIG. 21 Market Share of SMBG Testing in the InVitro- Diagnostic Market Globally
FIG. 22 Market Shares (U.S. Vs Others)
FIG. 23 SMBG Market Sizes & Growth Rate
FIG. 24 Market Share of SMBG Testing in InVitro- Diagnostic Market Globally
FIG. 25 Key Participants: Market Share
FIG. 26 Global Market Size & Growth Rate
FIG. 27 market share (2010)
FIG. 28 Global Diabetes Drug Market
FIG. 29 Global Anti-Diabetic Injectables Market
FIG. 30 Global Diabetes Injectables Drug Market
FIG. 31 Market Share of ABBOTT LABORATORIES
FIG. 32 Revenue Shares of ABBOTT LABORATORIES
FIG. 33 Revenue Trends of Dexcom
FIG. 34 Revenue Trends of Eli Lilly
FIG. 35 Revenue Contribution of Eli Lilly
FIG. 36 Revenue Trend of GLAXOSMITH
FIG. 37 Revenue Trend of GLAXOSMITH
FIG. 38 Revenue Trend of Glenmark Pharmaceuticals
FIG. 39 Revenue Contribution of Johnson&Johnson
FIG. 40 Revenue Trend of Johnson&Johnson
FIG. 41 Revenue Trend of LUPIN
FIG. 42 Revenue Trend of Roche
FIG. 43 Revenue Contribution of Sanofi
FIG. 44 Revenue Trend of Sanofi
No related posts.
Global Diabetes Devices Market & Diabetes Drugs Market (2011- 2016)Buy This Report Now Call US : USA-CANADA Toll Free: +1-866-997-948 or +1-518-618-1030 Email: sales@twease.org |
Request Sample on This Report
|